Managing neuropathic pain.
Pain may be the most common reason patients seek treatment from physicians. When persistent and unrelieved, pain can frustrate both the person suffering with this condition and the physician trying to alleviate it. Relief from such discomfort may be particularly difficult to achieve and fraught with misconceptions. Treatment usually requires trials of physical, pharmacologic, and surgical interventions to achieve resolution. In cases that remain insoluble, patients must accept partial relief and seek adaptive strategies. Sources of persistent pain may be nociceptive or neuropathic. Both utilize the same nerve pathways for transmission, but significant physiologic differences exist in mechanisms through which these painful stimuli are biologically processed and resolved. Nociceptive pain resulting from a known or obvious source (eg, trauma, cancer metastasis, ischemia, arthritis) is often easy to identify. Neuropathic pain, however, may occur in the absence of an identifiable precipitating cause. Physicians must remain alert to differences in presentation and course of neuropathic pain syndromes, some of which may be subtle or unusual.
Galluzzi
Katherine E
KE
Department of Geriatric Medicine, Philadelphia College of Osteopathic Medicine, 4190 City Ave, Suite 315, Philadelphia, PA 19131-1633, USA. katherineg@pcom.edu
D000588:Amines / Q000008:administration & dosage; D000701:Analgesics, Opioid / Q000627:therapeutic use; D000927:Anticonvulsants / Q000008:administration & dosage; D002121:Calcium Channel Blockers / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003509:Cyclohexanecarboxylic Acids / Q000008:administration & dosage; D003929:Diabetic Neuropathies / Q000188:drug therapy; D018450:Disease Progression; D004359:Drug Therapy, Combination; D000077206:Gabapentin; D006801:Humans; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D010523:Peripheral Nervous System Diseases / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D000069583:Pregabalin; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D014481:United States; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000031:analogs & derivatives
D000588:Amines; D000701:Analgesics, Opioid; D000927:Anticonvulsants; D002121:Calcium Channel Blockers; D003509:Cyclohexanecarboxylic Acids; D016194:Receptors, N-Methyl-D-Aspartate; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin